Cytiva and Nucleus Biologics Join Forces to Accelerate Development of Custom Cell Media for Cell and Gene Therapies
- Collaboration will enable transparent, cGMP, and scalable manufacture of custom cell culture media
Cytiva, a global life sciences leader, and Nucleus Biologics, LLC, The Cell Performance Company™, have signed a collaboration agreement on custom media formulation and fulfillment solutions for the cell and gene therapy industry. Utilizing Nucleus Biologics’ proprietary platform, Cytiva customers will have access to XURI Media AI Guide, an artificial intelligence platform for optimizing cell culture formulations, and XURI Media Designer System, a cell media configurator that enables customization of cell culture media while maintaining formulation ownership, in addition to ordering “off-the-shelf” cell culture media. Access to these platforms will accelerate the development of cellular therapies by making custom cell media available early during process development and simplifying downstream scale up.
Cell culture media is a critical component for bringing cell and gene therapies to market. Catarina Flyborg, Vice President, Cell and Gene Therapy, says: “One of Cytiva’s strengths is our ability to collaborate with other organizations to bring our customers the most innovative solutions. Our collaboration with Nucleus Biologics is a primary example of this. Together, we will provide our customers with solutions that will accelerate the development of cell and gene therapies.”
Cell and gene therapy manufacturers have typically relied on off-the-shelf cell culture media. Owning formulas and having access to a scalable custom media supply is a paradigm shift in cell therapy manufacturing and simplifies the development and commercialization processes.
David Sheehan, President and CEO, Nucleus Biologics, says: “Our collaboration with Cytiva will usher in a new era of customization of media for cell and gene therapies. Our innovative products and expertise in small lot manufacturing combined with Cytiva’s quality, industry experience, and impressive reputation will help scientists speed the time from discovery to cure.”
There were 1,320 industry sponsored and 1,328 non-industry sponsored regenerative and advanced therapy trials underway worldwide during the first half of 2021.1 By 2026, forecasts predict that there will 3,100 unique therapies in development2 creating an immediate need to provide customers with an option for cell culture media that is optimized to their drug’s quality attributes.
Customers can access XURI Media AI Guide and XURI Media Designer System through the Cytiva website. To learn more click here.
To learn more about Cytiva’ s cell and gene therapy solutions click here.
For more information about Nucleus Biologics click here.
1Alliance for Regenerative Medicine H1 2021 Report page 13
2Alliance for Regenerative Medicine H1 2021 Report page 16
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
About Nucleus Biologics, LLC.
Nucleus Biologics, The Cell Performance Company, is the leading provider of custom cell-growth media, tools and technologies for cell and gene therapy. Their mission is to speed the time from scientific discovery to cure by delivering innovative, transparent and cGMP products and services with the goal of disrupting the market and eliminating antiquated practices and products. Ultimately, Nucleus Biologics strives to create a new paradigm that serves both scientists and clinicians, while reducing the environmental footprint of cell culture. www.nucleusbiologics.com.
Media Contact:
Colleen Connolly
Colleen.Connolly@cytiva.com
+1 774 245 3893
Original source here.